Androgen-producing tissue

Androgen-producing tissue refers to the collective endocrine organs and cellular structures responsible for the biosynthesis of androgenic hormones, such as testosterone and dihydrotestosterone. The primary sites include the Leydig cells of the testes, the zona reticularis of the adrenal cortex, and the theca cells of the ovaries (StatPearls, 2024). These tissues utilize cholesterol as a precursor, converting it through a series of enzymatic steps involving proteins like CYP11A1 and CYP17A1 into active androgens. In pathological contexts like castration-resistant prostate cancer, the tumor microenvironment itself can function as an androgen-producing site through de novo steroidogenesis (Journal of Clinical Oncology, 2011). Therapeutic strategies targeting these tissues aim to deprive hormone-sensitive tumors of their growth stimulus, either through surgical removal or chemical suppression of the hypothalamic-pituitary axis. Common pharmacological approaches include the use of GnRH analogues to shut down gonadal production or enzyme inhibitors like abiraterone to block adrenal and intratumoral synthesis (PubChem). While effective for treating conditions like prostate cancer and hyperandrogenism, systemic suppression of these tissues often results in significant side effects related to hormone deficiency, including osteoporosis and metabolic dysfunction (NIH, 2023).

Other names

Steroidogenic tissueAndrogen-secreting tissueGonadal and adrenal tissuesExtratesticular androgen-producing tissue

Inhibition of steroidogenic enzymes (e.g., CYP17A1) within the tissue or indirect suppression via the hypothalamic-pituitary-gonadal (HPG) axis to reduce hormone output (StatPearls, 2024).